[{"address1": "Uppsalalaan 17", "address2": "3rd & 4th floor", "city": "Utrecht", "zip": "3584 CT", "country": "Netherlands", "phone": "31  30 253 8800", "website": "https://www.merus.nl", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.", "fullTimeEmployees": 260, "companyOfficers": [{"maxAge": 1, "name": "Mr. Gregory D. Perry", "age": 65, "title": "Chief Financial Officer", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 757509, "exercisedValue": 0, "unexercisedValue": 4198114}, {"maxAge": 1, "name": "Mr. Peter B. Silverman J.D.", "age": 47, "title": "EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 895170, "exercisedValue": 2414560, "unexercisedValue": 5740596}, {"maxAge": 1, "name": "Dr. Fabian  Zohren M.D., Ph.D.", "age": 49, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 637930, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jan G.J. van de Winkel Ph.D.", "title": "CEO & Executive Director", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hennie  Hoogenboom", "title": "Co-Founder and Scientific Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Harry  Shuman", "title": "Chief Accounting Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Cornelis Adriaan de Kruif Ph.D.", "age": 61, "title": "CTO & Executive VP", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 380471, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.", "title": "Chief Scientific Officer & Senior VP", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sherri  Spear", "title": "Senior Vice President of Investor Relations & Strategic Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kathleen  Farren", "title": "Director of IR & Corporate Communications Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 90.0, "open": 96.86, "dayLow": 87.14, "dayHigh": 96.86, "regularMarketPreviousClose": 90.0, "regularMarketOpen": 96.86, "regularMarketDayLow": 87.14, "regularMarketDayHigh": 96.86, "payoutRatio": 0.0, "beta": 1.062, "forwardPE": -17.648754, "volume": 2720520, "regularMarketVolume": 2720520, "averageVolume": 1253685, "averageVolume10days": 520523, "averageDailyVolume10Day": 520523, "bid": 69.74, "ask": 124.07, "bidSize": 200, "askSize": 200, "marketCap": 6826245632, "fiftyTwoWeekLow": 33.19, "fiftyTwoWeekHigh": 97.14, "allTimeHigh": 97.14, "allTimeLow": 7.255, "priceToSalesTrailing12Months": 120.59226, "fiftyDayAverage": 95.4148, "twoHundredDayAverage": 69.3443, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 6202397184, "profitMargins": 0.0, "floatShares": 70009856, "sharesOutstanding": 75847175, "sharesShort": 817936, "sharesShortPriorMonth": 1526984, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.0108, "heldPercentInsiders": 0.97045, "heldPercentInstitutions": 0.92802, "shortRatio": 0.59, "shortPercentOfFloat": 0.0108, "impliedSharesOutstanding": 75847175, "bookValue": 10.218, "priceToBook": 8.807985, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -381135008, "trailingEps": -5.28, "forwardEps": -5.09951, "enterpriseToRevenue": 109.571, "enterpriseToEbitda": -16.819, "52WeekChange": 1.2813687, "SandP52WeekChange": 0.11527538, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "MRUS", "underlyingSymbol": "MRUS", "shortName": "Merus N.V.", "longName": "Merus N.V.", "firstTradeDateEpochUtc": 1463664600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "42321671-9233-3f73-a2ee-487472589127", "messageBoardId": "finmb_24929296", "gmtOffSetMilliseconds": -18000000, "currentPrice": 90.0, "targetHighPrice": 97.0, "targetLowPrice": 97.0, "targetMeanPrice": 97.0, "targetMedianPrice": 97.0, "recommendationMean": 2.8, "recommendationKey": "hold", "numberOfAnalystOpinions": 9, "totalCash": 635932032, "totalCashPerShare": 8.385, "ebitda": -368772000, "totalDebt": 12317000, "quickRatio": 7.588, "currentRatio": 7.972, "totalRevenue": 56606000, "debtToEquity": 1.589, "revenuePerShare": 0.796, "returnOnAssets": -0.26533002, "returnOnEquity": -0.51568, "grossProfits": 20937000, "freeCashflow": -174430496, "operatingCashflow": -317267008, "revenueGrowth": 0.032, "grossMargins": 0.36987, "ebitdaMargins": 0.0, "operatingMargins": -7.94058, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2026-02-21"}]